Millennium: The Takeda Oncology Company Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma

Published: Jun 28, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating MLN9708 in patients with relapsed and/or refractory multiple myeloma. The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe, North America, Latin America and the Asia-Pacific region.

Back to news